Trofinetide: First Approval

[1]  E. Berry-Kravis,et al.  Trofinetide for the treatment of Rett syndrome: an open-label study in girls 2 to 4 years of age (P13-9.005) , 2023, Thursday, April 27.

[2]  X. García‐Mera,et al.  Concise Overview of Glypromate Neuropeptide Research: From Chemistry to Pharmacological Applications in Neurosciences , 2023, ACS chemical neuroscience.

[3]  J. Neul,et al.  Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage , 2022, Neuropsychiatric disease and treatment.

[4]  J. Roux,et al.  State‐of‐the‐art therapies for Rett syndrome , 2022, Developmental medicine and child neurology.

[5]  J. Youakim,et al.  A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects , 2022, Clinical Drug Investigation.

[6]  S. Peters,et al.  Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. , 2022, Contemporary clinical trials.

[7]  E. Marsh,et al.  Consensus guidelines on managing Rett syndrome across the lifespan , 2020, BMJ paediatrics open.

[8]  W. Kaufmann,et al.  Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome , 2019, Neurology.

[9]  M. Justice,et al.  Rett syndrome: a neurological disorder with metabolic components , 2018, Open Biology.

[10]  A. Kolevzon,et al.  A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. , 2017, Pediatric neurology.

[11]  R. Deacon,et al.  NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome , 2015, NeuroMolecular Medicine.

[12]  P. Gluckman,et al.  NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke , 2009, Journal of the Neurological Sciences.

[13]  Nathan R. Wilson,et al.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice , 2009, Proceedings of the National Academy of Sciences.

[14]  A. Yaroshinsky,et al.  A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. , 2017, Pediatric neurology.